Skip to main
Pharmacy BPC-157

A precision-registered readout of the BPC-157 literature — every recovery study, every pharmacokinetic figure, and where compounded access actually stands, laid down layer by layer.

The studies and FDA pages used here

Where can you check the BPC-157 sources?

Every BPC-157 study and FDA page cited here appears below. You can open each source and check the animal, human, and pharmacy facts yourself.

Go back to the study resultsRead what FDA says

How can you check one of these claims?

Each bracketed number leads to a full source below. The BPC-157 list begins with rat tendon work from the early 2000s, then a 2017 blood-flow study and a 2022 test of how animals cleared the compound.

Small human tests and reviews from 2024-2026 follow. FDA links show the agency's BPC-157 entries in its own words.

Each study entry gives the journal details and a direct link. The FDA entries lead to government pages, so you don't have to take this site's word for the pharmacy facts.

Most sources are animal or lab studies. Only a small group involved people, and none was a large controlled healing trial.

  1. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
  3. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
  4. Xue XC, Wu YJ, Gao MT, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. ↗
  5. Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716-725. ↗
  6. Pevec D, Novinscak T, Brcic L, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010;16(3):BR81-88. ↗
  7. Sikiric P, Gojkovic S, Knezevic M, et al. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. Biomedicines. 2022;10(12):3221. ↗
  8. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021. ↗
  9. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
  10. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  11. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024. ↗
  12. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Acute Pancreatitis. Medicina (Kaunas). 2025;61(2):291. ↗
  13. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions. Pharmaceuticals (Basel). 2025;18(10):1450. ↗
  14. Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System. Pharmaceuticals (Basel). 2026;19(1):145. ↗
  15. Sikiric P, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. ↗
  16. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (BPC-157 free base / BPC-157 acetate, Category 2; effective 2023-09-29) and Bulk drug substances used in compounding under section 503A of the FD&C Act. ↗
  17. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (Category 1 and Category 2 definitions; January 7, 2025 revised interim policy under which newly nominated substances are no longer placed in numbered categories). ↗
  18. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (BPC-157, KPV, TB-500, and MOTs-C listed as substances being considered for inclusion on the 503A Bulks List). ↗
  19. Tohyama Y, et al.. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyltryptophan autoradiographic measurements. Life Sci. 2004;76:345-357. ↗
  20. Boban Blagaic A, et al.. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol. 2005;512:173-179. ↗
  21. Chang CH, et al.. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19:19066-19077. ↗